Browsing Tag

Nasdaq:IMRX

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to…

Jason Junior Sep 2, 2022

CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations…

Health

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting…

Jason Junior May 27, 2022

IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical data package now includes animal studies showing the potential for broad activity across tumors driven by MAPK pathway…

Health

Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will…

Jason Junior Jan 7, 2022

Preclinical Data Suggest IMM-1-104 May Offer Unique Therapeutic Advantage Compared with Binimetinib in NRAS Mutant Tumors Data to be discussed in Key External Expert event on January 6 2022, 5PM Eastern Time CAMBRIDGE, Mass.,…

Health

Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International…

Jason Junior Oct 11, 2021

Preclinical Data Demonstrated Broad Antitumor Activity Across KRAS, NRAS and BRAF Mutant Tumor Models, Established Novel Mechanism of Action for its Dual MEK Inhibition and Showed Synergies with Sotorasib in KRAS-G12C Mutant Pancreatic…